Get the Stockscreener App
8.96
11.72%
0.94
After Hours:
8.80
-0.16
-1.79%
89 Bio Inc stock is traded at $8.96, with a volume of 3.85M.
It is up +11.72% in the last 24 hours and down -3.86% over the past month.
See More
Previous Close:
$8.02
Open:
$8.05
24h Volume:
3.85M
Relative Volume:
1.67
Market Cap:
$1.31B
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
-4.5482
EPS:
-1.97
Net Cash Flow:
$-165.54M
1W Performance:
+2.63%
1M Performance:
-3.86%
6M Performance:
+23.50%
1Y Performance:
-20.78%
1-Day Range:
$7.97
$9.318
1-Week Range:
$7.66
$9.318
52-Week Range:
$5.9857
$11.84
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
142 SANSOME STREET, SAN FRANCISCO, CA
Compare ETNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
8.96 | 1.31B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Resumed | BofA Securities | Buy |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-10-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-23 | Initiated | UBS | Buy |
| Jun-13-23 | Initiated | Evercore ISI | Outperform |
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
Victory Capital Management Inc. Acquires 1,437 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
PNC Financial Services Group Inc. Increases Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio (NASDAQ:ETNB) Given Sell (D-) Rating at Weiss Ratings - Defense World
89bio, Inc. (NASDAQ:ETNB) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $27.56 Average Target Price from Analysts - Defense World
89bio, Inc. (NASDAQ:ETNB) Shares Sold by Steward Partners Investment Advisory LLC - Defense World
89bio (NASDAQ:ETNB) Research Coverage Started at The Goldman Sachs Group - Defense World
Citigroup Initiates Coverage on 89bio (NASDAQ:ETNB) - Defense World
Goldman Sachs starts 89bio stock with neutral, $11 target By Investing.com - Investing.com Australia
Goldman Sachs Initiates Coverage of 89bio (ETNB) with Neutral Recommendation - Nasdaq
Goldman Sachs Initiates Coverage on 89bio With Neutral Rating, $11 Price Target -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Goldman Sachs starts 89bio stock with neutral, $11 target - Investing.com India
89bio initiated with a Neutral at Goldman Sachs - TipRanks
Commit To Buy 89bio At $7.50, Earn 25.1% Annualized Using Options - Nasdaq
Citigroup Initiates Coverage of 89bio (ETNB) with Buy Recommendation - Nasdaq
Citigroup Initiates 89bio Inc at Buy With $25 Price Target -March 13, 2025 at 07:13 am EDT - Marketscreener.com
89bio initiated with a Buy at Citi - TipRanks
Time nigh for I&I? Key data points ahead - BioWorld Online
89bio Inc (NASDAQ: ETNB) Is On The Fall - Stocks Register
89bio (NASDAQ:ETNB) Earns Sell (D-) Rating from Weiss Ratings - Defense World
Rhumbline Advisers Has $1.02 Million Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - Citeline News & Insights
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
New York State Common Retirement Fund Has $128,000 Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Can 89bio's Liver Disease Pipeline Impress Investors at Upcoming Leerink Conference? - StockTitan
Cantor maintains Overweight on 89bio stock, price target at $29 - Investing.com
Cantor maintains Overweight on 89bio stock, price target at $29 By Investing.com - Investing.com UK
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy - Investing.com
89bio’s (ETNB) “Buy” Rating Reiterated at HC Wainwright - Defense World
89Bio Inc. Faces Financial Risks Amid Market Challenges for Approved Products - MSN
Decoding 89bio Inc (ETNB): A Strategic SWOT Insight - GuruFocus.com
89bio Inc. Advances Clinical Trials Amid Financial Losses - TipRanks
89bio (NASDAQ:ETNB) Stock Price Down 9.1%What's Next? - MarketBeat
89bio (NASDAQ:ETNB) Announces Earnings Results, Misses Estimates By $0.42 EPS - MarketBeat
Cantor Fitzgerald maintains 89bio stock with $29 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains 89bio stock with $29 target - Investing.com
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - The Globe and Mail
89bio, Inc. SEC 10-K Report - TradingView
89bio Secures $727.5M War Chest While Advancing Critical Phase 3 Trials — What's Next for ETNB? - StockTitan
89bio (ETNB) Projected to Post Earnings on Thursday - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $31.43 Consensus PT from Brokerages - Defense World
Weiss Ratings Reaffirms "Sell (D-)" Rating for 89bio (NASDAQ:ETNB) - MarketBeat
Cell Sorting Market Size to Hit USD 601.89 Million by 2034 - BioSpace
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High? - MSN
89bio, Inc. (NASDAQ:ETNB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Should You Buy 89BIO (ETNB) After Golden Cross? - Nasdaq
Weiss Ratings Reiterates Sell (D-) Rating for 89bio (NASDAQ:ETNB) - Defense World
89bio Inc (NASDAQ: ETNB) Is A Buzzing Hot Stock - Stocks Register
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):